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Predicting pregnancy complications is a major topic for clinicians and biologists for maternal and fetal monitoring. Noninvasive
biomarkers in maternal blood such as circulating microRNAs (miRNAs) are promising molecules to predict pregnancy disorders.
miRNAs are noncoding short RNAs that regulatemRNAexpression by repressing the translation or cleaving the transcript.miRNAs
are released to the extracellular systemic circulation via exosomes. The discovery of plasma- or serum-derived miRNAs and of
free-circulating exosomes that contain miRNAs provides useful information about the physiological or pathophysiological roles
of the miRNAs. Specific placental miRNAs are present in maternal plasma in different ways depending on whether the pregnancy
is normal or pathological or if there is no pregnancy. This paper focuses on placental miRNAs and extracellular miRNAs to the
placenta whose misregulation could lead to pregnancy complications.
1. Introduction
The discovery of fetal DNA in maternal blood has opened
new perspectives on noninvasive prenatal diagnosis devel-
opment [1]. Since then, other fetal specific nucleic acids
related to placenta circulating throughout the plasma and
the serum of pregnant women have been found: mRNA
[2] and miRNA [3]. Specific placental miRNAs circulating
through the plasma reflect the physiological state of preg-
nancy and are undetectable after delivery [4]. This suggests
that their concentration and their profiles in the plasmamake
them possible candidates as biomarkers for the detection
of pregnancy complications linked to placental pathologies.
The identification of specific placental miRNAs in maternal
blood as noninvasive biomarkers in pregnancy management
is developing rapidly. Early noninvasive diagnosis techniques
could facilitate medical monitoring for both the mother and
the fetus. In this paper, we review themisregulated expression
of circulating placental miRNAs related to specific pregnancy
pathologies.These molecules could be promising biomarkers
for noninvasive diagnosis or the prediction of preeclampsia,
intrauterine growth restriction, and early pregnancy loss.
2. MicroRNAs
In the early 2000s the term microRNA (miRNA) was first
introduced. MicroRNAs are small noncoding RNAs about
20–24 nucleotides long. These molecules have been shown
to play critical regulatory roles in a wide range of biological
and pathological processes [5].miRNAs regulate cellular gene
expression at the posttranscriptional level by suppressing the
translation of protein coding genes. This process is made
possible by the perfect pairing of miRNAs and mRNAs or
their imperfect pairing leading to cleft mRNAs of protein
coding genes. In both cases the pairing is performed at 3󸀠UTR
(untranslated region) or 5󸀠UTR of mRNA [6]. The miRNA
biogenesis is a multistep complex process (Figure 1): miRNA
genes are transcribed as primary miRNA (pri-miRNA) in the
nucleus by the enzyme RNA pol II. RNA pol II is bound to
the promoter region of a specific DNA sequence and forms
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Figure 1: miRNA biogenesis. miRNA gene is transcribed by RNA pol II to form a hairpin loop primary transcript, pri-miRNA, which is
processed by Drosha/DCGR8 to form pre-miRNA. Pre-miRNA is exported to the cytoplasm by exportin 5 where Dicer cleaves off the hairpin
loop to form a duplex that contains the mature miRNA. The mature miRNA is then incorporated into the RNA-induced silencing complex
RISC to target the 3󸀠 untranslated region of the target mRNA to silence expression by repression or cleavage.
the pri-mRNA which presents a hair pin structure. This pri-
miRNA transcript is processed by the Drosha endonuclease
associated with the double-stranded RNA binding protein
DGCR8 to form the precursor miRNA (pre-miRNA) by
cleaving the nucleotides on both sides of the hair pin. Pre-
miRNAs are exported by exportin 5 into the cytoplasm. The
stem-loop miRNA is then processed by the Dicer RNase III
endonuclease to produce the double-strand mature miRNA.
ThematuremiRNA is associatedwithAgo2 to form the RNA-
induced silencing complex (RISC), which prevents target
mRNAs expression in a specific manner relative to the
stability of the bound of the RISC complex at 3󸀠UTR on the
target mRNA [5].When the sequences are perfectly matched,
the RISC complex is bound tightly to the mRNA; and the
mRNA is degraded by the enzymeAgo2.When the sequences
are not perfectly matched, the RISC complex inhibits the
translation of the mRNA without degradation. The two
different pathways lead to the same final outcome: a decrease
in the protein level of the target gene [7]. RISC complex
can be bound efficiently not only on the 3󸀠UTR but also
on the 5󸀠UTR of the target mRNA to inhibit the translation
[6]. The binding with 3󸀠UTR has been well studied; however
the binding with 5󸀠UTR needs further investigation to better
understand this regulation. Interestingly, recent studies have
shown that animal miRNAs are able not only to repress,
but also to activate gene expression by acting on mRNA
stability and translational regulation [8].The binding of RISC
complex on 5󸀠UTR is a necessary condition for the translation
activation. It has been shown that the association of miRNAs
with 5󸀠UTR generally induces translation activation rather
than repression [9].
According to the miRNA database, today 2578 mature
and 1872 precursor forms of miRNAs have been identified
in humans [10]. One of the first identified characteristics
of the miRNAs is the very well conserved sequences in all
species and these are expressed in tissues, in a specificmanner
[11]. miRNAs are critical in cell development, proliferation,
communication, and tissue differentiation. They have been
involved in regulating pregnancies [5]. Aberrant miRNA
expression patterns have been found in pathologies and phys-
iological processes including pregnancy and angiogenesis
[12].
3. MicroRNA Functions in
Human Placental Development
Development of the human placenta is critical for embry-
onic development and successful pregnancy. Differentiation,
migration, invasion, angiogenesis, proliferation, and apop-
tosis mechanisms play an important role in key processes
of placental development [13, 14]. The first step begins with
the implantation of the blastocyst followed by the formation
of various trophoblast cell types from the outer epithelial
layer of the blastocyst, the trophectoderm [13]. Primitive
syncytium is generated from the invasive trophoblast cell
type migrating into the maternal endometrium. After the
formation of the lacuna system, which is the ancestor of
the intervillous space, cytotrophoblasts emanating from the
trophectodermal layer produce primary villi by proliferation
and invasion through the primitive syncytium.These primary
villi change into secondary and tertiary villi characterized by
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the invasion of extraembryonic mesenchymal cells, villous
branching, and vascularization. The cytotrophoblast fuses
into multinucleated syncytiotrophoblasts which are eventu-
ally in close contact with placental vessels allowing efficient
nutrient uptake by the fetus [14].
Studies have shown that miRNAs are produced in the
human placenta and their expression is regulated by envi-
ronmental factors such as hypoxia, signaling pathways, and
epigenetic modification [15–17]. MicroRNAs are expressed in
different ways during the various stages of placental develop-
ment relative to their functions in regulating placental devel-
opment and trophoblast cell activities [12]. miRNAs regulate
placental development and functions through trophoblast
cell proliferation, apoptosis, migration, invasion, and angio-
genesis: miR-378a-5p [18], miR-376c [19], and miR-141 [20]
enhance trophoblast cell proliferation whereas miRNA-155
[21] and miRNA-675 [22] inhibit this process. Apoptosis of
trophoblast cells is induced by miR-29b [23] and inhibited by
miR-182 [24]. It has been shown that miRNAs are involved
in trophoblast cell migration and invasion: miR-376c [19]
and miR-378a-5p [18] enhance trophoblast migration and
invasion; miR-195 [25] and miR-21 [26, 27] promote tro-
phoblast invasion. Conversely, miR-210 [28], miR-34a [29],
and miR-29b [23] reduce trophoblast cell invasion; miR-155
[30] has an inhibiting effect on trophoblast cell migration. In
placental angiogenesis, the abundant expression of Dicer in
the perivascular villous stroma suggests that miRNAs play a
role in placental vascularization and spiral artery remodeling
[31]. It has been shown that miR-16 and miR-29b reduce
placental angiogenesis [12].
More than 500miRNAs are expressed in the human
placenta which exhibits a specific miRNA expression pat-
tern [11]. Numerous miRNAs, which are predominantly or
exclusively expressed during pregnancy, are clustered in
chromosomal regions andwork synergistically [32].The three
most significant miRNA clusters are C19MC and miR-371-
3 cluster (located on chromosome 19) and C14MC (located
on chromosome 14) [33]. C19MC and C14MC are specifically
expressed in the placenta [26, 34]. C19MC is the largest
miRNA cluster identified with 46 pre-miRNAs transcribed
only in the placenta [35] and expressed from the paternal
allele [36]. C14MC contains 46 miRNAs and is encoded
by maternally imprinted genes [17]. miR-371-3 cluster is
adjacent to C19MC and contains 3 miRNAs. The expression
of C19MC and miR-371-3 miRNAs increases from the first to
the third trimester while C14MC miRNAs decrease during
the same period [33].These different expressions suggest that
the placental miRNAs have specific functions at the various
stages of the pregnancy.
Despite these interesting findings, the majority of pla-
cental miRNAs remain unknown. Only a small number of
placental specific miRNAs have been studied for their role in
placental development. Hence further research is required in
this study.
4. Circulating Placental MicroRNA
In 1997, the discovery by Lo et al. of fetal cell free DNA in
the plasma of pregnant women has led to the development
of noninvasive diagnostic methods based on maternal blood
for clinical applications such as fetal rhesus D genotyping,
fetal sex determination, and recently fetal chromosomal
aneuploidy detection [37]. With the discovery of miRNAs
expression in placental tissue, new molecules with a strong
diagnostic potential role as biomarkers for pregnancy-related
diseases should be considered, inasmuch as circulating miR-
NAs have been detected in maternal plasma [3].The absolute
concentration of fetal DNA increases with the pregnancy as
the fetus and the placenta grow [38]. Yet, it has been outlined
that circulating miRNA concentration varies depending on
the type of miRNA during the three trimesters of pregnancy
[39, 40]. Therefore, the noninvasive circulating placental
miRNA quantification for prenatal diagnosis should be per-
formed in a specific time of the gestational age, preferably
during the first trimester for early treatment or management
of complicated pregnancies.
MicroRNAs are exported from placental syncytiotro-
phoblasts and released into the maternal blood flow via
exosomal nanoparticles [41]. Exosomes are small 60–80 nm
membrane vesicles that are secreted by a multitude of cell
types as a consequence of fusion of multivesicular lyso-
somes/late endosomes with the plasma membrane. Depend-
ing on their original tissue, exosomes can come into play in
different physiological processes [42]. Exosomes originating
from the placenta have played a crucial role in setting up
an immune privilege for the developing fetus. Compared to
nonpregnant women, exosomes are found in larger quantities
in pregnant women [43]. Exosomes can be isolated from
blood sample, for in vivo or in vitro studies from specific tis-
sues of the human cell line performed by ultracentrifugation,
and then visualized by electron microscopy [44] (Figure 2).
In addition to the exosomal pathway, extracellular miRNAs
derived from human trophoblasts can be released from the
trophoblast layers in other forms, like microvesicles, apop-
totic bodies, and protein-bound miRNAs [45]. Circulating
miRNAs have been found to be complexed with circulating
ribonucleoprotein andhigh-density lipoproteins [45, 46].The
extracellular formofmiRNAs gives them relative stability and
protection fromdigestion by RNase in human blood [41] thus
reinforcing these small molecules as potential biomarkers.
5. Identification of Specific
Circulating MicroRNA Expression
Linked to Placental Pathology
Placental miRNAs are instrumental in placentation mecha-
nisms such as trophoblast proliferation, syncytialization, and
invasion. This has impact upon the major human placen-
tal diseases such as preeclampsia [47], intrauterine growth
restriction [48], and early pregnancy loss [49]. The misreg-
ulated expression of placental circulating miRNAs has been
detected in maternal blood with pregnancy complications
(Table 1).
To identify miRNA biomarkers for noninvasive diagnosis
on maternal blood of specific placental diseases, the first
step is to describe precisely the expression of miRNAs in
both normal and pathological human placentae of a specific
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Table 1: Altered expression of circulating placental miRNA in maternal blood with pregnancy complication for potential application in
noninvasive diagnosis.
Pregnancy complication miRNA upregulated miRNA downregulated References
Preeclampsia
miR-210 [50]
miR-376c [19]
miR-24, miR-26a, miR-103, miR-130b,
miR-181a,
miR-342-3p, miR-574-5p
[65]
miR-144 [47]
IUGR
miR-516-5p, miR-517, miR-518b,
miR-520a, miR-520h, miR-525,
miR-526a
[39]
miR-27a-1, miR-30d,
miR-93, miR-141,
miR-200c, miR-205,
miR-224, miR-335,
mir-424, miR-451, miR-491
[48]
Early pregnancy loss
miR-17, miR-19a
Found only on placental tissue
To be validated on maternal blood
[49]
100nm
Figure 2: Isolated exosomes analyzed on electron microscopy.
disease using microarray or next generation sequencing
methods to characterize the misregulated miRNAs in the
pathology: the miRNAs are either under- or overregulated.
Once the miRNAs have been determined as either under- or
overregulated, they are studied by real-time PCR to establish
the repeatability of the results both in the placenta and the
maternal blood to identify biomarkers for clinical application
[4]. A few expression studies have shown that the expression
of miRNAs may not be the same in the placenta and in
the maternal blood for certain pathologies. However other
studies have shown that miRNAs in plasma or in the placenta
increase or decrease at the same rate [47, 48].
The human placenta is a highly invasive and proliferative
structure. Successful placentation is the one and only way
to establish optimal blood and nutrient supply for normal
growth.The invasive capacity is similar to cancer cell invasion
with which it shares similar mechanisms.Therefore, miRNAs
involved in human cancer and referred to as oncomiRs can be
analyzed to suggest important miRNAs for placentation [49].
6. MicroRNA as Noninvasive
Biomarkers in Preeclampsia
Preeclampsia (PE) is amajor cause ofmaternal and fetal mor-
bidity or mortality, preterm birth, and intrauterine growth
restriction. This disease is characterized by maternal high
blood pressure. If the systolic blood pressure is greater
than 140mmHg, the diastolic blood pressure is greater than
90mmHg, and proteinuria occurs after 20 weeks’ gestation,
then one can diagnose the mother with preeclampsia. [47].
Risk factors for preeclampsia are maternal age, primiparity,
previous preeclampsia, multiple fetuses during the same
pregnancy, diabetes, high blood pressure, kidney disease,
autoimmune diseases, the antiphospholipid syndrome, obe-
sity, previous history, and ethnicity [47]. Preeclampsia is often
diagnosed in the third trimester of the pregnancy; but the
disorder is present long before the clinical symptoms appear
[50]. Despite the lack of therapeutic treatment, predicting
preeclampsia is a state-of-the-art method for managing
pregnancy and improving the health of both the mother
and the fetus. At present, there are no reliable biomarkers
for early detection of preeclampsia because most of them
are not sensitive or specific enough for clinical diagnosis
[51]. To enhance the predictive value of the diagnosis, it
is necessary that new biomarkers be found. Several stud-
ies have placed emphasis on proteins and metabolites in
biofluids [51] but few have been concerned with miRNAs,
which are yet becoming a promising class of biomarkers.
Some studies have compared miRNAs expression on pla-
centa between normal pregnancies and pregnancies with
minor and severe preeclampsia; these studies have led to the
identification of specific miRNAs involved in preeclampsia.
Misregulated miRNAs were analyzed in maternal plasma for
researching noninvasive biomarkers. MiR144 is significantly
underexpressed both in severe andminor preeclampsia when
compared with normal control [47]. Misregulation cases of
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miRNAs circulating in the plasma are more frequent in
minor than in severe preeclampsia as opposed to the placenta
tissue. These dysregulated miRNAs circulating in the plasma
may be associated with the early pathological preeclampsia
related changes. AnothermiRNA,miR-210, has been found to
significantly increase in the plasma of preeclampsia-affected
women [50].
Preeclampsia is a consequence of inadequate placental
cytotrophoblast invasion, trophoblast invasion, andmaternal
spiral artery remodeling. These lead to reduced uteroplacen-
tal perfusion pressure and oxygen availability which in turn
results in placental ischemia and hypoxia [52]. miR-144 is an
important regulator in ischemia and hypoxia [47] and miR-
210 is induced by hypoxia and regulated by transcriptional
factor HIF-1 (hypoxia inducible factor) and NF-𝜅B [53].
Moreover, another research has shown that miR-210 inhibits
trophoblast invasion [50]. These findings and the above-
mentioned ones show that miR-144 and miR-210 play an
important role in the pathogenesis of PE and that they might
be useful biomarkers for the diagnosis of preeclampsia.
7. MicroRNAs as Noninvasive Biomarkers in
Intrauterine Growth Restriction
Intrauterine growth restriction (IUGR), also known as fetal
growth restriction (FGR), is characterized as birth weight less
than the 10th percentile of the expected weight relative to
the gestational age and the sex of the fetus. IUGR increases
the risk of perinatal complications considerably [54]. IUGR
has been traced to a malfunction of the placenta along with
uteroplacental insufficiency at the interface between fetal and
maternal circulation [55]. The uteroplacental insufficiency
leads to deteriorated placenta transport of nutrients, mainly
amino acids, lipids [56], and micronutrients such as iron
and folate [57]. Preeclampsia, aneuploidies, or any genetic
syndrome is major risk factors of IUGR.Themother’s dietary
deficiencies, her exposure to environmental factors, and
placental epigenetic modifications are additional risk factors
[58].
The role of miRNAs in IUGR has not yet been clearly
understood compared to preeclampsia. However, we know
that miR-141 contributes to IUGR by regulating pleomorphic
adenoma gene 1 (PLAG1) expression [59]. The expression
level of miR-141 in the placenta of pregnancies with IUGR is
3.4 times greater than that in normal placentae. Besides, the
expression level of the miR-141 target gene, that is, PLAG1,
decreases significantly in the IUGRplacental tissue compared
to controls. PLAG1 ismainly expressed in the placenta during
pregnancy [59]. Another miRNA, miR-424, is a critical
mediator of oxygen-dependent miRNAs; it is physiologically
overregulated in placentae undergoing abnormal vascular
development. Increased levels of miR-424 in placenta with
IUGR have been found [60].
Local placental miRNAs such as mir-518b, mir-1323,
mir-516b, mir-515-5p, mir-520h, mir-519d, and mir-526b
are significantly lower in placentae in IUGR pregnancies
compared to normal ones. However the corresponding cir-
culating miRNA level does not change significantly [55].
This discrepancy has also been found for specific miRNAs
regulated by hypoxia (miR-27a, miR-30d, miR-141, and miR-
200c). The same observations are applicable to the following
ubiquitous miRNA species (miR-205, miR-424, miR-451,
and miR-491) and miRNAs from cluster C19MC known to
be expressed mainly by the placenta (miR-517a, miR-518b,
miR-518e, and miR-524) [48]. However, the overall level of
these twelve specific miRNAs increases in the plasma of
women with IUGR complicated pregnancies. The difference
inmisregulation level of themiRNAs between the plasma and
the placenta may be indicative of placental injury in IUGR;
placental injury lowers miRNA biogenesis while increasing
the release of miRNAs onto the plasma [48].
Another high level of pregnancy-related extracellular
miRNAs (miR-516-5p, miR-517, miR-518b, miR-520a, miR-
520h, miR-525, and miR-526a) has been observed at the
early stage of the pregnancy (between the 12th and the 16th
weeks of gestation) in late-onset IUGR as opposed to normal
pregnancies [39]. What has already been discovered needs
to be completed to find reliable biomarkers for noninvasive
diagnosis of IUGR on maternal plasma.
8. MicroRNAs as Noninvasive Biomarkers in
Early Pregnancy Loss
The fetal loss before 20 weeks of pregnancy is called early
pregnancy loss or miscarriage. This is a common event
which complicates up to 15%of pregnancies [61].Mechanisms
leading to early pregnancy loss from noncytogenetic causes
are related to defective trophoblast growth and impaired inva-
siveness by trophoblast cells leading to defective placentation
[62].
Few studies have focused on miRNA implication and
misregulation in early pregnancy loss. miR-17 and miR-19a
are strikingly underregulated in the placenta when it comes
to early spontaneous miscarriage [49]. This suggests that the
above-mentioned miRNAs may play a critical role in early
placentation. These results obtained from placenta samples
have yet to be confirmed for maternal plasma to identify
noninvasive miRNA biomarkers in early pregnancy loss.
9. Conclusion
miRNAs are relatively stable and expressed specifically
depending on the various tissues. This makes them ideal
candidates for diagnosis. The close link between altered
expression of miRNAs in maternal plasma and pathological
pregnancies has been well described.
Circulating miRNAs provide a new fetal genetic material
easily collectable from maternal blood samples. They offer
new potential for the development of noninvasive prenatal
diagnostic tests.
Implementing noninvasive prenatal diagnosis usingmiR-
NAs involves the analysis of the misregulatedmiRNAs linked
to the pathology. Under- or overexpressed miRNAs can
be analyzed by relative quantification using real-time PCR.
Important points need to be included when reporting inves-
tigation of cell-free microRNAs such as sample collection,
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miRNA isolation and quantification, and the normalization
methods [63]. As for the screening of Down syndrome in
maternal serum [64], the design of noninvasive tests to antic-
ipate pregnancy complications should include results with
multiple of the median (MoM) for each miRNA analyzed for
measuring the level of the misregulation. Additionally, a risk
should be calculated from biological and clinical parameters.
National or international studies should be performed to
determine the cut-off risk to conclude to a low or high risk
for developing the pathology.
Discoveries of potential miRNAs for noninvasive
biomarkers should be improved by deeper analyses and
appropriate normalization methods to confirm the results
obtained prior to application for clinical care. The levels
of circulating miRNAs change relative to the gestational
age. Studies have to include results for each trimester of the
pregnancy. Then, microRNAs circulating in the maternal
plasmamight have the potential to be noninvasive diagnostic
and prognostic biomarkers for pregnancy monitoring. They
might prevent the development of gestational disorders and
form the basis of personalized therapeutic strategies.
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